Related by context. All words. (Click for frequent words.) 72 chronic lymphocytic leukemia 69 myeloma 69 metastatic breast cancer 69 acute myeloid leukemia 68 lymphoma 68 metastatic melanoma 68 glioblastoma 67 pancreatic cancer 67 chronic lymphocytic leukemia CLL 66 HER2 positive breast cancer 66 cancer 66 non Hodgkin lymphoma 66 melanoma 66 CLL 66 colon cancer 65 acute myelogenous leukemia AML 65 colorectal cancer 65 leukemia 65 leukemia AML 64 hematologic malignancies 64 renal cell carcinoma 64 metastatic colorectal cancer 64 lupus 64 metastatic colon cancer 64 myelofibrosis 63 ovarian cancer 63 NSCLC 63 acute myelogenous leukemia 63 liver cancer 63 Multiple Myeloma 63 relapsed multiple myeloma 63 lung cancer 62 lupus nephritis 62 acute myeloid leukemia AML 62 follicular lymphoma 62 lymphoma CTCL 62 prostate cancer 62 Hodgkin lymphoma 62 bladder cancer 62 hormone refractory prostate cancer 61 advanced NSCLC 61 acute leukemia 61 chronic myelogenous leukemia 61 malignant melanoma 61 Crohn disease 61 Lymphoma 61 myelodysplastic syndrome 61 solid tumors 61 myelodysplastic syndrome MDS 61 multiple myeloma MM 61 metastatic prostate cancer 61 sarcoma 61 leukemia ALL 61 acute lymphoblastic leukemia 60 indolent NHL 60 HER2 positive metastatic breast 60 metastatic cancer 60 gastrointestinal stromal tumor GIST 60 Acute Myelogenous Leukemia AML 60 Revlimid 60 leukemia CLL 60 Velcade 60 idiopathic pulmonary fibrosis IPF 60 refractory multiple myeloma 60 Non Hodgkin Lymphoma 60 systemic lupus erythematosus 60 HRPC 60 cell lung cancer 60 gastric cancer 60 relapsed ovarian cancer 59 malignant pleural mesothelioma 59 relapsing remitting multiple sclerosis 59 breast cancer 59 Waldenstrom macroglobulinemia 59 hematological malignancies 59 Sutent 59 cell lymphoma 59 relapsed leukemia 59 carfilzomib 59 metastatic renal cell carcinoma 59 hematological cancers 59 bortezomib 59 Non Hodgkin lymphoma 59 myelodysplastic syndromes 59 non Hodgkin Lymphoma 59 chronic myeloid leukemia CML 59 cancers 59 cell lymphoma CTCL 59 hematological malignancy 59 Acute Myeloid Leukemia 58 clofarabine 58 Non Hodgkins lymphoma 58 dasatinib 58 DLBCL 58 chronic myeloid leukemia 58 rheumatoid arthritis 58 gastrointestinal stromal tumors 58 severe sepsis 58 relapsed refractory 58 chemotherapy regimens 58 pancreatic adenocarcinoma 58 bile duct cancer 58 recurrent ovarian cancer 58 malignancies 58 Hodgkin lymphoma NHL 58 Hodgkin Lymphoma 58 soft tissue sarcoma 58 metastatic disease 58 relapsed refractory multiple myeloma 58 metastatic kidney 58 Revlimid lenalidomide 57 erlotinib 57 diagnosed multiple myeloma 57 carcinoid cancer 57 brain metastases 57 abiraterone 57 pomalidomide 57 hematologic disorders 57 HCV infection 57 Amrubicin 57 Acute Myelogenous Leukemia 57 Velcade bortezomib 57 Herceptin trastuzumab 57 B CLL 57 differentiated thyroid 57 lymphoblastic leukemia 57 Pancreatic Cancer 57 tyrosine kinase inhibitors TKIs 57 metastatic lung cancer 57 Rituxan rituximab 57 rituximab 57 Folotyn 57 Tarceva erlotinib 57 chemotherapy 57 Acute Lymphoblastic Leukemia 57 inoperable pancreatic cancer 57 recurrent NSCLC 57 medullary thyroid cancer 57 docetaxel chemotherapy 57 psoriasis 57 cutaneous T cell 56 ixabepilone 56 VELCADE 56 Acute myeloid leukemia 56 metastatic 56 esophageal cancer 56 sorafenib Nexavar ® 56 Myeloma 56 rheumatoid arthritis RA 56 ALS 56 lymphoblastic lymphoma 56 Glioblastoma Multiforme 56 Rituxan 56 glufosfamide 56 acute leukemias 56 tyrosine kinase inhibitors 56 myeloid leukemia 56 smoldering myeloma 56 YONDELIS 56 bone metastasis 56 idiopathic pulmonary fibrosis 56 multiple sclerosis 56 sorafenib 56 Chronic Lymphocytic Leukemia CLL 56 pleural mesothelioma 56 thalidomide Thalomid 56 abiraterone acetate 56 amyotrophic lateral sclerosis ALS 56 chronic myelogenous leukemia CML 56 Acute Myeloid Leukemia AML 56 Annamycin 56 Alzheimer disease 56 Mantle Cell Lymphoma 56 hepatocellular carcinoma HCC 56 Hodgkin lymphoma HL 56 metastatic malignant melanoma 56 metastatic pancreatic cancer 56 metastatic renal cell 56 pancreatic NET 55 Friedreich Ataxia 55 heavily pretreated 55 neuroendocrine tumors 55 vandetanib 55 HER2 positive 55 cell lymphomas 55 lymphatic cancer 55 soft tissue sarcomas 55 temozolomide 55 sunitinib 55 IV metastatic melanoma 55 gastrointestinal cancers 55 systemic lupus erythematosus SLE 55 panobinostat 55 gemcitabine chemotherapy 55 bone metastases 55 neuroblastoma 55 Ewing sarcoma 55 brain tumor glioblastoma multiforme 55 eculizumab 55 lymphocytic leukemia 55 Zolinza 55 chemotherapies 55 pertuzumab 55 sunitinib malate 55 lenalidomide Revlimid R 55 non hodgkin lymphoma 55 myelodysplastic syndromes MDS 55 tumors GIST 55 Burkitt lymphoma 55 nonsmall cell lung cancer 55 stem cell transplant 55 hepatocellular carcinoma 55 resistant ovarian cancer 55 chemotherapy regimen 55 azacitidine 55 GVHD 55 imatinib Gleevec 55 Avastin 55 Myelodysplastic Syndrome MDS 55 SCCHN 55 Amyotrophic Lateral Sclerosis ALS 55 anticancer therapy 55 biologic therapy 55 gemcitabine 55 temsirolimus 55 Yervoy 55 dasatinib Sprycel 55 Targretin 55 Follicular lymphoma 55 juvenile myelomonocytic leukemia 55 systemic ALCL 55 castration resistant prostate cancer 55 AA amyloidosis 55 medulloblastoma 55 cisplatin chemotherapy 55 Gleevec imatinib 55 docetaxel 55 Chronic lymphocytic leukemia 55 Alessandro Riva 55 malignant mesothelioma 55 prostate cancer CRPC 54 tamibarotene 54 obatoclax 54 GvHD 54 acute promyelocytic leukemia 54 anthracycline taxane 54 refractory metastatic colorectal cancer 54 Acute Leukemia 54 Xanafide 54 myeloproliferative disorders 54 CTCL 54 chemotherapeutic agent 54 prostate cancer HRPC 54 Dacogen 54 cetuximab 54 tesetaxel 54 irinotecan chemotherapy 54 Glioblastoma 54 neuroendocrine cancer 54 glioblastoma multiforme GBM 54 imatinib Gleevec ® 54 Myelodysplastic Syndrome 54 axitinib 54 mRCC 54 non Hodgkins Lymphoma 54 Hodgkin Disease 54 vinorelbine 54 CHOP chemotherapy 54 Tarceva 54 ipilimumab 54 trastuzumab 54 metastatic hormone refractory 54 recurrent glioblastoma multiforme 54 tafamidis 54 standard chemotherapy regimens 54 bendamustine 54 cytotoxic chemotherapy 54 FOLOTYN 54 mCRC 54 metastatic cancers 54 metastatic bladder 54 non Hodgkins lymphoma 54 Chronic Lymphocytic Leukemia 54 HCV 54 gastrointestinal stromal tumor 54 tanespimycin 54 cell acute lymphoblastic 54 lapatinib 54 erlotinib Tarceva ® 54 malignancy 54 Nexavar 54 Gleevec 54 cystic fibrosis CF 54 disease progression 54 Torisel 54 myeloproliferative neoplasms 54 BRAF inhibitor 54 leukaemias 54 leukemia APL 54 sarcomas 54 Acute Myeloid Leukaemia AML 54 AP# [003] 54 Herceptin 54 trabectedin 54 docetaxel Taxotere 53 cystic fibrosis 53 anti TNF 53 pulmonary fibrosis 53 Campath alemtuzumab 53 aHUS 53 ofatumumab 53 galiximab 53 refractory AML 53 lumiliximab 53 GIST 53 metastatic CRC 53 Pharmion Vidaza 53 relapsed MM 53 chronic myeloid 53 leukemias 53 cetuximab Erbitux 53 chemotherapeutic agents 53 cabazitaxel 53 liver disease 53 basal cell carcinoma BCC 53 Hepatocellular Carcinoma HCC 53 bevacizumab Avastin 53 Idiopathic Pulmonary Fibrosis IPF 53 Cholangiocarcinoma 53 Burkitt Lymphoma 53 metastatic RCC 53 lymphomas 53 bone marrow transplantation 53 taxane therapy 53 tivozanib 53 ulcerative colitis 53 Non Hodgkins Lymphoma 53 imatinib 53 scleroderma 53 acute lymphoblastic 53 Vidaza 53 Bayer Nexavar 53 Spinal Muscular Atrophy SMA 53 bortezomib Velcade R 53 T DM1 53 refractory myeloma 53 relapsing multiple sclerosis 53 Novartis Gleevec 53 mycophenolate mofetil 53 Taxotere ® 53 ALS Amyotrophic Lateral Sclerosis 53 indolent lymphoma 53 gynecological cancers 53 IMGN# 53 chlorambucil 53 disease modifying 53 G CSF 53 gastrointestinal stromal tumors GIST 53 TTR amyloidosis 53 nonmelanoma skin cancers 53 recurrent GBM 53 relapsed SCLC 53 refractory indolent non 53 voreloxin 53 systemic scleroderma 53 paroxysmal nocturnal hemoglobinuria PNH 53 carboplatin paclitaxel 53 FSGS 53 monoclonal antibody therapies 53 Myelofibrosis 53 proteasome inhibitor bortezomib 53 Neulasta ® 53 pirfenidone 53 essential thrombocythemia 53 pralatrexate 53 ankylosing spondylitis 53 Telintra 53 hypophosphatasia 53 Fludara 53 pazopanib 53 platinum refractory 53 Crohn Disease 53 pancreatic neuroendocrine tumors 53 relapsing remitting MS 53 panitumumab Vectibix 53 thyroid cancer 53 Ewing Sarcoma 53 HGS# 53 chronic GVHD 53 hemolytic anemia 53 panitumumab 53 Ceflatonin 53 Doxil ® 53 anaplastic thyroid cancer 53 Melanoma 53 MDV# 53 acute promyelocytic leukemia APL 53 Aplidin 53 squamous cell cancer 53 alvespimycin 53 osteosarcoma 53 Arcalyst 53 refractory ovarian cancer 53 Krabbe disease 53 refractory acute myeloid 53 chronic kidney 53 figitumumab 53 kidney disease 53 PARP inhibitors 53 Lou Gerhig disease 53 Mozobil 53 MGUS 53 mTOR inhibitor 53 myelodysplasia 53 chronic ITP 53 amrubicin 53 non metastatic osteosarcoma 53 neoadjuvant treatment 53 pegylated liposomal doxorubicin 53 advanced carcinoid 53 enzastaurin 53 systemic lupus 53 nilotinib 53 perifosine 53 colorectal cancer CRC 53 hematological diseases 53 investigational therapies 53 docetaxel Taxotere R 52 brain tumors 52 macroglobulinemia 52 heavily pretreated patients 52 Vectibix 52 PLX# 52 inflammatory arthritis 52 cutaneous T 52 HNSCC 52 cancer mCRC 52 Multiple myeloma 52 chronic lymphatic leukemia 52 irinotecan 52 superficial bladder cancer 52 sorafenib Nexavar 52 COPD 52 refractory CLL 52 imetelstat 52 Amyotrophic lateral sclerosis ALS 52 Erbitux cetuximab 52 OncoVEX GM CSF 52 PNP inhibitor 52 romiplostim 52 cardiovascular disease 52 non squamous 52 Li Fraumeni Syndrome 52 haematologic malignancies 52 Xcytrin 52 CYT# potent vascular disrupting 52 taxane chemotherapy 52 ELACYT 52 allogeneic bone marrow 52 recurrent glioblastoma 52 sapacitabine 52 prostate cancer mCRPC 52 OHR/AVR# 52 hepatocellular cancer 52 refractory chronic lymphocytic 52 Multiple Sclerosis 52 commercialize deforolimus 52 Chronic Myeloid Leukemia 52 acute myelogenous 52 squamous cell 52 metastatic colorectal 52 Jevtana 52 PTLD 52 refractory PTCL 52 immunotherapy 52 Friedreich ataxia 52 Evoltra ® 52 haematological cancers 52 fallopian tube carcinoma 52 follicular lymphoma FL 52 Revlimid pill 52 Taxotere R 52 Rituximab 52 Nexavar sorafenib 52 Symadex 52 endometrial cancer 52 non squamous NSCLC 52 bevacizumab Avastin ® 52 Cutaneous T 52 Cytoxan 52 TEMODAL 52 Cloretazine 52 Arzerra ofatumumab 52 SJIA 52 liposomal doxorubicin 52 TREANDA 52 Myelodysplastic syndromes MDS 52 non Hodgkin lymphomas 52 Acute Lymphocytic Leukemia 52 metastatic NSCLC 52 sickle cell disease 52 hematopoietic cell 52 Amigal 52 allogeneic stem cell 52 visilizumab 52 dacetuzumab 52 amyloidosis 52 rhabdomyosarcoma 52 relapsed CLL 52 gefitinib Iressa 52 MabThera Rituxan 52 Prostate cancer 52 diabetic nephropathy 52 refractory colorectal cancer 52 Chronic Myeloid Leukemia CML 52 Myelodysplastic syndrome 52 picoplatin 52 acute lymphocytic leukemia 52 Taxotere docetaxel 52 Erbitux 52 Alimta 52 chemoradiotherapy 52 neratinib 52 liver metastases 52 trastuzumab Herceptin 52 palifosfamide 52 Erlotinib 52 Duchenne muscular dystrophy 52 xenograft models 52 atypical hemolytic uremic syndrome 52 Merck KGaA Erbitux 52 Gleevec imatinib mesylate 52 pancreatic cancers 52 Pemetrexed 52 autoimmune disease 52 Marqibo 52 angiogenesis inhibitor 52 Advexin 52 Chronic Myeloid Leukaemia 52 interferon 52 Gleevec resistant 52 CMV disease 52 Duchenne Muscular Dystrophy 52 relapsing MS 52 cilengitide 52 Zarnestra 52 pulmonary arterial hypertension 52 radiation sensitizer 52 Pixantrone 52 Cloretazine ® 52 Alemtuzumab 52 Troxatyl 52 hematologic cancers 52 Treanda 52 Dacogen injection 52 Myelodysplastic syndromes 52 dacarbazine 52 Alzhemed TM 52 cancer cachexia 52 therapeutic regimens 52 ganetespib 52 neuroendocrine cancers 52 inherited neurodegenerative disorder 51 myeloablative 51 tyrosine kinase inhibitor 51 polycystic kidney disease 51 monotherapy 51 refractory CTCL 51 EGFR inhibitors 51 pemetrexed Alimta 51 cell malignancies 51 Alzheimers disease 51 baminercept 51 thymic carcinoma 51 bowel cancer 51 ankylosing spondylitis AS 51 imatinib resistance 51 neurodegenerative disease 51 common hematologic malignancy 51 Duchenne muscular dystrophy DMD 51 tofacitinib 51 paclitaxel Taxol 51 Acute lymphoblastic leukemia 51 diffuse intrinsic pontine glioma 51 anthracyclines 51 Zytiga 51 depsipeptide 51 basal cell nevus syndrome 51 Atiprimod 51 REVLIMID 51 Asentar 51 Doxil 51 metastatic gastric 51 cirrhosis liver failure 51 paclitaxel Taxol ® 51 relapsing remitting 51 FOLFOX chemotherapy 51 capecitabine Xeloda 51 advanced hepatocellular carcinoma 51 Cystinosis 51 anti angiogenic therapy 51 tumors 51 Parkinson disease 51 pancreatic islet cell 51 Duchenne Muscular Dystrophy DMD 51 Hodgkins Disease 51 leukemias lymphomas 51 dasatinib Sprycel ® 51 haematological malignancies 51 ovarian lung 51 synovial sarcoma 51 Non Hodgkin 51 Clolar 51 Cloretazine R 51 dexpramipexole 51 SUTENT 51 vismodegib 51 elotuzumab 51 decitabine 51 Alzheimer 51 myelofibrosis MF 51 infusional 5-FU/LV 51 Acute Myeloid Leukaemia 51 PXD# 51 Chronic myeloid leukemia CML 51 IV malignant melanoma 51 idiopathic thrombocytopenic purpura ITP 51 Amyotrophic lateral sclerosis 51 Halaven 51 MGd 51 invasive breast cancer 51 relapsed 51 erlotinib Tarceva 51 mycosis fungoides 51 relapsed acute myelogenous 51 TORISEL 51 adalimumab Humira 51 dirucotide 51 Gleevec Glivec 51 unresectable 51 evaluating tivozanib 51 Avastin bevacizumab 51 chronic ITP patients 51 carcinoma 51 phenoxodiol 51 ovarian cancers 51 colorectal cancers 51 anti leukemic 51 elacytarabine 51 Leukemia lymphoma 51 VIDAZA 51 chronic granulomatous disease 51 fludarabine 51 T#I mutation 51 CLL SLL 51 cetuximab Erbitux ® 51 progressive supranuclear palsy 51 entinostat 51 colorectal lung 51 chemoradiation 51 cytogenetic responses 51 Soliris 51 Taxotere 51 hepatitis C HCV 51 eribulin 51 Waldenstrom Macroglobulinemia 51 Sutent sunitinib 51 HER2 overexpression 51 TKI therapy 51 capecitabine Xeloda R 51 IV melanoma 51 farletuzumab 51 advanced metastatic renal 51 Ceflatonin R 51 indolent follicular non 51 BAY #-# 51 JAK inhibitor 51 chronic plaque psoriasis 51 nucleoside analogues 51 satraplatin 51 PROVENGE 51 squamous cell carcinoma SCC 51 inoperable lung cancer 51 MPS VI 51 TKIs 51 papillary renal cell carcinoma 51 neuronal ceroid lipofuscinosis NCL 51 Sprycel dasatinib 51 Actemra 51 aflibercept 51 Omacetaxine 51 myelofibrosis polycythemia vera 51 cetuximab Erbitux R 51 immune thrombocytopenic purpura 51 hepatitis C 51 immunosuppressive therapies 51 Hodgkins Lymphoma 51 Gemzar ® 51 relapsing remitting MS RRMS 51 Metastatic breast cancer 51 T#I [002] 51 anaplastic astrocytoma 51 Stomach cancer 51 prostrate cancer 51 molecularly targeted 51 Leber Congenital Amaurosis LCA 51 metastatic GIST 51 refractory Hodgkin lymphoma 51 grade gliomas 51 forodesine 51 Bortezomib 51 AML 51 leukemia lymphoma 51 pegfilgrastim 51 hypereosinophilic syndrome 51 romidepsin 51 metastatic CRPC 51 maribavir 51 PD LID 51 angiosarcoma 51 pediatric acute lymphoblastic 51 anti TNF alpha 51 severe oral mucositis 51 antibody MAb 51 Fludara ® 51 carcinoid tumors 51 Nicole Onetto MD 51 imatinib resistant 51 ASA# 51 seminoma 51 glioblastomas 51 Celgene Revlimid 51 CD# antibody [001] 51 bosutinib 51 cytarabine 51 ThermoDox R 51 Severe Primary IGFD 51 Interferon alpha 51 olaparib 51 follicular non 51 Seliciclib 51 Idiopathic Pulmonary Fibrosis 51 TRISENOX 51 multiple sclerosis MS 51 stem cell transplantation 51 proteasome inhibitor 51 complete remissions 51 mapatumumab 51 lung fibrosis 51 basal cell carcinomas 51 Leukemia 51 malignant pleural mesothelioma MPM 51 gefitinib 51 cisplatin 51 pancreatic carcinoma 51 cardiotoxicity 51 familial ALS 50 biliary cancer 50 aplastic anemia 50 sepsis 50 glioblastoma multiforme 50 standard chemotherapy regimen 50 VEGF inhibitors 50 interferon therapy 50 Ontak 50 cell lymphoma ALCL 50 postherpetic neuralgia 50 basiliximab 50 denosumab 50 fibromyalgia syndrome 50 chronic HCV infection 50 Metastatic melanoma 50 immunotherapeutic 50 Fanconi anemia 50 Evoltra TM 50 iniparib 50 topotecan 50 bortezomib Velcade 50 lymphoma leukemia 50 cystinosis 50 demethylating agents 50 vasculitis 50 terlipressin 50 eosinophilic asthma 50 Afinitor 50 therapies 50 Alzheimer disease AD 50 pediatric malignancies 50 idarubicin 50 rituximab Rituxan 50 HDAC inhibitors 50 homozygous familial hypercholesterolemia 50 INCB# [001] 50 Hodgkin disease 50 Aflibercept 50 relapsed GBM 50 gastric cancers 50 HuMax CD4 50 metastatic malignant 50 gemcitabine Gemzar ® 50 metastatic squamous cell carcinoma 50 breast tumors 50 VEGF Trap 50 Pompe disease 50 Rituxan MabThera 50 AEG# 50 Pompe Disease 50 psoriasis rheumatoid arthritis 50 FOLFIRI 50 dirucotide MBP# 50 ZACTIMA 50 Triapine 50 TELINTRA 50 IV NSCLC 50 systemic mastocytosis 50 KRAS wild 50 brain tumor 50 stage IIIB IV 50 hormone deprivation 50 proteasome inhibitors 50 pulmonary arterial hypertension PAH 50 refractory chronic myeloid 50 eltrombopag 50 ADVEXIN 50 bevacizumab 50 OXi# 50 Hodgkins lymphoma 50 HGS ETR1 50 tocilizumab 50 doxorubicin Adriamycin 50 refractory CML 50 TACE 50 anticancer agents 50 PEGylated interferon beta 1a 50 follicular NHL 50 oxypurinol 50 T Cell Lymphoma 50 interferon alpha 50 metaglidasen 50 post herpetic neuralgia PHN 50 sorafenib tablets 50 marrow transplant 50 stage IIIb 50 Vandetanib 50 interferons 50 Arranon 50 demonstrated antitumor activity 50 Xelox 50 adjuvant therapy 50 Campath 50 ADPKD 50 severe aplastic anemia 50 renal disease 50 debilitating autoimmune 50 Gorlin syndrome 50 Acute Lymphoblastic Leukaemia 50 Osteosarcoma 50 Glivec 50 lapatinib Tykerb 50 Aryplase 50 phase IIb clinical 50 BRAF V# mutation 50 prostate cancer PCa 50 refractory SCLC 50 humanised monoclonal antibody 50 RSR# 50 pulmonary fibrosis PF 50 oral clodronate 50 Rhabdomyosarcoma 50 Parkinson Disease 50 angiogenesis inhibition 50 secondary hyperparathyroidism 50 pegylated interferon alpha 50 Krabbe Disease 50 trastuzumab Herceptin ® 50 IGF 1R inhibitor 50 huN# DM1 50 myelogenous leukemia 50 thymoma 50 beta interferon 50 Chronic lymphocytic leukemia CLL 50 chemotherapy induced neutropenia 50 vemurafenib 50 operable breast cancer 50 Eliezer Zomer Ph.D. 50 Imprime PGG 50 chronic HCV 50 Vidaza azacitidine 50 receptor tyrosine kinase inhibitor 50 Folfox 50 Genasense ® 50 efalizumab 50 colorectal liver metastases 50 malignant brain 50 immunosuppressant 50 IPF 50 Cimzia TM 50 medulloblastomas 50 remission induction 50 metastatic castration resistant 50 tigecycline 50 Panzem NCD 50 refractory metastatic 50 Ewings Sarcoma 50 malignant pheochromocytoma 50 Hurler syndrome 50 ependymoma 50 esophageal cancers 50 oral deforolimus 50 PKC# 50 EGFR expressing 50 familial amyloidotic polyneuropathy FAP 50 MabThera 50 Pancreatic cancer 50 MyVax R 50 bone marrow transplant 50 Azacitidine 50 Proxinium TM 50 advanced metastatic prostate 50 pulmonary hypertension 50 interstitial lung disease 50 ZEVALIN 50 EGFR expressing mCRC 50 refractory prostate cancer 50 esophageal adenocarcinoma 50 adecatumumab 50 anthracycline 50 candidemia 50 basal cell carcinoma 50 Rheumatoid Arthritis 50 myeloproliferative neoplasms MPNs 50 ON #.Na 50 tasisulam 50 EndoTAGTM 1 50 vorinostat 50 pulmonary hypertension PH 50 docetaxel Taxotere ® 50 cell carcinoma 50 PKCi 50 anti angiogenic agents 50 erythropoietic 50 nasopharyngeal carcinoma 50 refractory APL 50 alkylating agent 50 hepatoblastoma 50 chronic HBV infection 50 cediranib 50 polycythemia vera 50 Hycamtin 50 HER2 + 50 Gastric cancer 50 Renal Cell Carcinoma RCC 50 severe psoriasis 50 DIPG 50 relapsed AML 50 vinca alkaloid 50 non hodgkins lymphoma 50 potentially hepatotoxic 50 Fludarabine 49 Lapatinib 49 Dasatinib 49 gemcitabine carboplatin 49 untreated multiple myeloma 49 cholangiocarcinoma 49 anticancer therapies 49 ADHF 49 Taxotere chemotherapy 49 SPRYCEL ® 49 Belldegrun 49 cell carcinoma RCC 49 Nephrotic Syndrome 49 nab paclitaxel 49 pixantrone 49 GW# [003] 49 autoantibody positive 49 Sorafenib 49 Wegener granulomatosis 49 lenalidomide Revlimid 49 bladder cancers 49 psoriatic arthritis 49 neovascular diseases 49 RRMS 49 malignant lymphoma 49 cell chronic lymphocytic 49 serous ovarian cancer 49 TTF Therapy 49 acute GvHD 49 zanolimumab 49 immune thrombocytopenic purpura ITP 49 androgen receptor antagonist 49 nephritis 49 myeloproliferative diseases 49 Sunitinib 49 dyskeratosis congenita 49 Cushing Syndrome 49 Cloretazine R VNP#M 49 LHON 49 huC# DM4 49 MDS AML